10:20 AM EDT, 04/05/2024 (MT Newswires) -- Natera ( NTRA ) said Friday an analysis from a phase 3 study of muscle-invasive bladder cancer patients using its Signatera blood test yielded positive results.

The company said the analysis of the study, which was presented at the European Association of Urology Congress in Paris, showed an overall survival rate of 100% at 12 months and 98% at 18 months in patients whose molecular residual disease test remained negative.

Natera ( NTRA ) said the study data indicates that patients "who remain MRD-negative on serial testing may be spared from adjuvant treatment."

Shares of Natera ( NTRA ) rose 3% in recent trading Friday, paring earlier gains.

Price: 95.09, Change: +2.73, Percent Change: +2.96